ClinicalTrials.gg
Not yet recruitingNCT07951242Updated Nov 20, 2026

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of a Children's Fiber Blend on Digestive Health and Gut Microbiome Composition in Children

An interventional study of Children's Fiber Blend and Placebo in Constipation, Microbiome and Bloating, sponsored by LOAM Science. Not yet recruiting. Open to participants aged 3 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by LOAM Science · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
3 Years to 6 Years
Sex
All
01

Study summary

This study evaluates the impact of a fiber blend supplement on gastrointestinal symptoms and the gut microbiome in children aged 3-6 with a history or irregular stooling.

02

Conditions studied

  • Constipation
  • Microbiome
  • Bloating

Browse trials for

03

In context

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

This study's planned enrollment of 100 is above the median of 75 across 889 interventional studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

LOAM Science is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female child, aged 3-6 years (inclusive) at the time of enrollment.
  • Caregiver reports the child consumes few vegetables, whole fruit, whole grains, or legumes per week (fewer than two per day on average), consistent with this study's operational definition of low dietary fiber intake.
  • Caregiver reports infrequent or difficult bowel movements (constipation) in the child over the past four weeks
  • Caregiver reports the child has experienced excess gas, or bloating, over the past four weeks
  • Caregiver is willing and able to administer the study product to the child once daily with a meal for 4 weeks, complete digital questionnaires at Baseline, Weeks 1, 2, 3, and End of Study on behalf of the enrolled child, and to facilitate at-home microbiome stool sample collection at Baseline and End of Study and return samples per provided instructions.
  • Child is generally healthy, without any acute or chronic condition that would preclude safe participation as determined by caregiver report.
  • Caregiver is willing to maintain the child's current diet, sleep patterns, and activity levels throughout the study duration, and to avoid introducing new fiber supplements or probiotic/prebiotic products during the study period.
  • Caregiver and child reside in the United States.
  • Caregiver is willing and able to provide ; child assent will be obtained where age-appropriate and consistent with IRB requirements.

Exclusion criteria

Exclusion Criteria:

  • Known milk allergy, dairy allergy, lactose intolerance, or any known sensitivity to milk-derived products. (The study product's active formulation contains a milk allergen.)
  • Child is currently breastfeeding.
  • Known allergy or sensitivity to any component of the study product.
  • Currently receiving anticoagulant or antiplatelet medications (e.g., warfarin), due to potential interaction with Vitamin K2 contained in the study product.
  • Diagnosis of, or current treatment for, any gastrointestinal disease or disorder, including but not limited to: inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac disease, or diagnosed functional gastrointestinal disorders requiring medical management.
  • Use of any prescription or over-the-counter laxative, stool softener, antidiarrheal medication, or fiber supplement on a regular basis (≥3 times per week) in the 4 weeks prior to enrollment, or intent to use during the study.
  • Use of oral antibiotics or antifungals within 4 weeks prior to enrollment, or anticipated use during the study period.
  • Use of any probiotic or prebiotic supplement (other than those naturally occurring in diet) in the 4 weeks prior to enrollment, or intent to use during the study.
  • Significant acute illness, including fever, acute gastrointestinal infection, or other acute medical condition at the time of enrollment, or any chronic medical condition, developmental condition, or disability that, in the caregiver's judgment or per clinical guidance, would prevent the child from safely adhering to the study protocol.
  • Any planned surgical procedure during the 4-week study period.
  • Participation in another research study currently or within the past 30 days, or planned participation in any other research study during this study's duration.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Fiber Blend

    Dietary Supplement: Children's Fiber Blend

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementChildren's Fiber Blend

    This fiber blend contains a blend of Bifidogenic fibers and HMOs

  • Dietary supplementPlacebo

    Color and taste matched placebo.

06

What researchers measure

Primary outcomes

  1. Stool Frequency

    Caregiver reported number of bowel movements per week

    Time frame: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)

  2. Stool Consistency

    Caregiver reported stool consistency using the pediatric-adapted Bristol Stool Scale (one-seven, with one indicating hard lumpy stools and seven indicating soft liquid stools)

    Time frame: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)

  3. Digestive Comfort

    Digestive comfort assessed using a visual analog scale (one-five, with one being very bad and five being very good)

    Time frame: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)

Secondary outcomes

  1. Microbiome Composition

    Determined using shotgun metagenomic sequencing

    Time frame: Baseline, End of Study (Week 4)

  2. Gas and Bloating

    Gas and bloating assessed using a visual analog scale (one-five, with one being never bloated and five being always bloated)

    Time frame: Baseline, Week 1, Week 2, Week 3, End of Study (Week 4)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Data is proprietary

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 3 months is below that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2027
CompletionEst.
Jul 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951242
Lead sponsor
LOAM Science
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Bryce Jarman
Contact
bryce@loamscience.com
323-325-1327

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion